Antibodies News and Research

RSS

Type 1 diabetes incidence rose by 11% after rotavirus vaccine rollout in Norway

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in Diabetologia (the journal of EASD) shows that incidence (the new case rate) of type 1 diabetes (T1D) in children aged 0.5-5 years in Norway was 11% higher following the rapid roll out and uptake of the rotavirus vaccine in September 2014.

1 Oct 2026

Varying mutation rates in healthy organs explain cancer risk

A new study by scientists at City of Hope® and TGen, part of City of Hope, found surprisingly large differences in the number of mutations present in organs of healthy individuals.

1 Oct 2026

Trevogrumab cuts semaglutide-induced lean mass loss by half, study shows

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and in press with The Lancet shows that using the trevogrumab to inhibit myostatin, a protein that negatively regulates muscle mass, can reduce lean mass loss during treatment with semaglutide by 50% compared with semaglutide and placebo.

1 Oct 2026

AtlasPlex™ brings custom 5-plex IHC on FFPE tissue into a single day

Atlas Antibodies has launched AtlasPlex™, a new ready-to-use multiplex immunohistochemistry kit. It lets researchers build their own 3- or 5-plex panels from more than 17,000 IHC-validated antibodies covering over 12,000 human genes.

From Atlas Antibodies AB 30 Sep 2026

Atlas Antibodies marks 20 years of Human Protein Atlas–validated antibodies

Atlas Antibodies is 20 years old. The company is the original manufacturer of the antibodies used to map the human proteome in the Human Protein Atlas (HPA).

From Atlas Antibodies AB 30 Sep 2026

MolBoolean™ measures free and bound proteins in the same experiment

Atlas Antibodies has launched MolBoolean™, a new in situ proximity assay. It detects free protein A, free protein B, and the A–B complex together in fixed cells and tissue.

From Atlas Antibodies AB 30 Sep 2026

An approved Ebola antibody may miss its mark against Bundibugyo virus

Researchers analyzed 44 Bundibugyo virus genomes and modeled how approved and experimental Ebola antibodies might bind the virus’s glycoprotein. The models predicted disrupted binding for Ebanga, conserved targets for MBP134, and different binding behavior for the complete Inmazeb cocktail than for two of its antibodies alone; laboratory tests are needed to determine whether these findings translate into treatment benefit.

28 Sep 2026

New EASD study highlights red meat sugar as independent risk factor for type 2 diabetes

Preliminary results of an observational study being presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2), reveal that a sugar called dietary N-glycolylneuraminic acid (Neu5Gc), which is common in red meat, is independently associated with a 63% higher risk of developing type 2 diabetes (T2D) in those with the highest versus lowest consumption, even after taking into account other T2D risk factors such as level of physical activity, overall diet, smoking status and other health conditions.

28 Sep 2026

Review highlights emerging treatments for glioblastoma multiforme

A new research perspective was published in Volume 13 of Oncoscience on September 17, 2026, titled "Emerging pharmacological agents for glioblastoma multiforme: An update on active clinical trials (2025–2026)."

25 Sep 2026

Laser irradiation boosts antibody-antigen interactions to detect colorectal cancer

Researchers often use antibodies to detect specific molecules or biological markers, as they are remarkably precise at recognizing their targets.

25 Sep 2026

Better storage buffers could pave way for safer mRNA therapies

Researchers at The University of Texas at Austin have teamed up with pharmaceutical leader Eli Lilly and Company to uncover new information about mRNA lipid nanoparticles (LNPs), the technology behind COVID-19 vaccines and other important treatments, and how to make it more effective.

25 Sep 2026

EGFR co-targeting and nanotechnology offer new triple-negative breast cancer therapies

Triple-negative breast cancer (TNBC) remains one of the most challenging forms of breast cancer to treat because it lacks the estrogen, progesterone and HER2 receptors that enable targeted treatment in other breast cancer subtypes.

24 Sep 2026

MLC1 auto-antibodies identified as possible trigger for NMOSD-like diseases

NMOSD is an inflammatory autoimmune disorder that damages support and supply cells in the central nervous system, known as astrocytes.

22 Sep 2026

Mpox study reveals high rate of false-positive PCR tests

In August 2024, the WHO declared the mpox upsurge in the Democratic Republic of the Congo (DRC), and its spread to neighboring countries, a Public Health Emergency of International Concern.

22 Sep 2026

City of Hope develops adaptive plug-and-play CAR T technology to attack tumors

Researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the country, have developed a new "plug-and-play" technology that adds engineered molecules to chimeric antigen receptor (CAR) T cells after treatment, allowing scientists to better control the cells and redirect them to attack different types of cancer.

22 Sep 2026

Sugary drinks stood out in this stomach cancer study, but diet drinks did not

In two large US prospective cohorts, consuming more than one sugar-sweetened beverage a day was associated with higher gastric cancer incidence compared with consuming less than one serving a month. Artificially sweetened beverages were not associated with gastric cancer incidence, and the authors called for further studies to confirm the findings and clarify possible biological mechanisms.

21 Sep 2026